Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:472dcc37695ffd08b7d6adee3960422c' in /persistent/html/includes/cache.inc on line 26.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving anastrozole together with fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in treating postmenopausal women with metastatic breast cancer.</p>\n', created = 1283575668, expire = 1283662068, headers = '', serialized = 0 WHERE cid = '1:472dcc37695ffd08b7d6adee3960422c' in /persistent/html/includes/cache.inc on line 109.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:546a511c51e555740a57fc3d83cd2ed2' in /persistent/html/includes/cache.inc on line 26.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer</p>\n', created = 1283575668, expire = 1283662068, headers = '', serialized = 0 WHERE cid = '1:546a511c51e555740a57fc3d83cd2ed2' in /persistent/html/includes/cache.inc on line 109.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:17d5f738c9cdce243b0b46f561101f17' in /persistent/html/includes/cache.inc on line 26.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>OBJECTIVES:\n<ul>\n<li>Compare the time to tumor progression in postmenopausal women with metastatic breast cancer treated with anastrozole with or without fulvestrant as first-line therapy.</li>\n<li>Compare the clinical benefit (complete or partial response, confirmed or unconfirmed, or stable disease ≥ 24 weeks) and overall survival of patients treated with these regimens.</li>\n<li>Compare adverse events in patients treated with these regimens.</li>\n<li>Determine the prognostic significance of estrogen receptor positivity and HER2/neu status in patients treated with these regimens.</li>\n<li>Determine parameters of estrogen and clinical pharmacology and estrogen levels in patients treated with these regimens.</li>\n<li>Compare anastrozole plasma levels at 8, 16, and 24 weeks in patients treated with these regimens.</li>\n<li>Compare estradiol serum levels at 8, 16, and 24 weeks in patients treated with these regimens.</li>\n</ul>\n</p><p> OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior adjuvant tamoxifen therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.\n<ul>\n<li>Arm I: Patients receive oral anastrozole once daily on days 1-28.</li>\n<li>Arm II: Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</li>\n</ul>\n</p><p> Patients are followed for up to 4 years. PROJECTED ACCRUAL: A total of 690 patients (345 per treatment arm) will be accrued for this study within 3 years.</p>\n', created = 1283575668, expire = 1283662068, headers = '', serialized = 0 WHERE cid = '1:17d5f738c9cdce243b0b46f561101f17' in /persistent/html/includes/cache.inc on line 109.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:6ca2aecd78fb8e2a73ec7ab40dbc322b' in /persistent/html/includes/cache.inc on line 26.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>DISEASE CHARACTERISTICS:\n<ul>\n<li>Histologically confirmed breast cancer meeting 1 of the following criteria:\n<ul>\n<li>Metastatic disease (M1)</li>\n<li>Multiple sites of new disease that is clinically obvious metastatic disease (e.g., multiple sites of new osseous disease)</li>\n</ul>\n</li>\n<li>Measurable or nonmeasurable disease</li>\n<li>No known brain or CNS metastases</li>\n<li>Hormone receptor status:\n<ul>\n<li>Estrogen-receptor positive* AND/OR</li>\n<li>Progesterone-receptor positive* NOTE: *Positivity defined as estrogen binding of > 10 fmol/mg cytosol protein by ligand binding assay or positive by immunohistochemistry</li>\n</ul>\n</li>\n</ul>\n</p><p> PATIENT CHARACTERISTICS: Age\n<ul>\n<li>Not specified</li>\n</ul>\n</p><p> Sex\n<ul>\n<li>Female</li>\n</ul>\n</p><p> Menopausal status\n<ul>\n<li>Postmenopausal, as defined by 1 of the following:\n<ul>\n<li>Prior bilateral oophorectomy</li>\n<li>More than 12 months since last menstrual period with no prior hysterectomy</li>\n<li>At least 55 years of age with prior hysterectomy</li>\n<li>Under 55 years of age with a prior hysterectomy without oophorectomy and with estradiol and follicle-stimulating hormone levels consistent with menopause</li>\n</ul>\n</li>\n</ul>\n</p><p> Performance status\n<ul>\n<li>Zubrod 0-2</li>\n</ul>\n</p><p> Life expectancy\n<ul>\n<li>Not specified</li>\n</ul>\n</p><p> Hematopoietic\n<ul>\n<li>No bleeding diathesis (e.g., disseminated intravascular coagulation or clotting factor deficiency)</li>\n</ul>\n</p><p> Hepatic\n<ul>\n<li>INR ≤ 1.6</li>\n</ul>\n</p><p> Renal\n<ul>\n<li>Not specified</li>\n</ul>\n</p><p> Other\n<ul>\n<li>HIV negative</li>\n<li>No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission</li>\n</ul>\n</p><p> PRIOR CONCURRENT THERAPY: Biologic therapy\n<ul>\n<li>No prior immunotherapy for recurrent or metastatic disease</li>\n</ul>\n</p><p> Chemotherapy\n<ul>\n<li>No prior chemotherapy for recurrent or metastatic disease</li>\n<li>More than 12 months since prior adjuvant or neoadjuvant chemotherapy</li>\n<li>No concurrent chemotherapy for malignancy</li>\n</ul>\n</p><p> Endocrine therapy\n<ul>\n<li>Prior adjuvant hormonal therapy allowed</li>\n<li>At least 12 months since prior adjuvant luteinizing hormone-releasing hormone (LHRH) analogues\n<ul>\n<li>Menstrual periods must not have resumed since LHRH therapy</li>\n</ul>\n</li>\n<li>More than 12 months since prior adjuvant or neoadjuvant aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane)</li>\n<li>More than 12 months since prior fulvestrant</li>\n<li>No prior hormonal therapy for recurrent or metastatic disease</li>\n<li>No other concurrent hormonal therapy for malignancy</li>\n<li>No concurrent hormone replacement therapy</li>\n</ul>\n</p><p> Radiotherapy\n<ul>\n<li>Not specified</li>\n</ul>\n</p><p> Surgery\n<ul>\n<li>Not specified</li>\n</ul>\n</p><p> Other\n<ul>\n<li>No long-term anticoagulant therapy (except antiplatelet therapy)</li>\n</ul>\n</p>', created = 1283575668, expire = 1283662068, headers = '', serialized = 0 WHERE cid = '1:6ca2aecd78fb8e2a73ec7ab40dbc322b' in /persistent/html/includes/cache.inc on line 109.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a9cf1b60cee59581ac836c2a5fd32de1' in /persistent/html/includes/cache.inc on line 26.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>Overall survival [ Designated as safety issue: No ]</p>\n', created = 1283575668, expire = 1283662068, headers = '', serialized = 0 WHERE cid = '1:a9cf1b60cee59581ac836c2a5fd32de1' in /persistent/html/includes/cache.inc on line 109.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:a944dd655d8028608c8443d8a2e9c579' in /persistent/html/includes/cache.inc on line 26.
- user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>Clinical response rates [ Designated as safety issue: No ]</p>\n', created = 1283575668, expire = 1283662068, headers = '', serialized = 0 WHERE cid = '1:a944dd655d8028608c8443d8a2e9c579' in /persistent/html/includes/cache.inc on line 109.
Trial phase:
Phase III
Recruitment status:
Recruiting RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving anastrozole together with fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in treating postmenopausal women with metastatic breast cancer.
Conditions
Asthma
Brain and Central Nervous System Tumors
Breast Cancer
Cancer
Cardiovascular Diseases
Colorectal Cancer
Depression
Healthy
Heart Diseases
HIV Infections
Hypertension
Leukemia
Lung Cancer
Lymphoma
Myelodysplastic Syndromes
Obesity
Ovarian Cancer
Prostate Cancer
Schizophrenia
Unspecified Adult Solid Tumor, Protocol Specific
Clinical trial sponsors
AstraZeneca
Bristol-Myers Squibb
Department of Veterans Affairs
Eli Lilly and Company
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
GlaxoSmithKline
Hoffmann-La Roche
M.D. Anderson Cancer Center
Memorial Sloan-Kettering Cancer Center
Merck
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)
Novartis
Pfizer
Sanofi-Aventis
User login
Study design
Active Control
Cohort
Crossover Assignment
Dose Comparison
Double-Blind
Double Blind (Subject, Investigator)
Efficacy Study
Non-Randomized
Open Label
Other
Parallel Assignment
Placebo Control
Prevention
Prospective
Randomized
Safety/Efficacy Study
Safety Study
Single Group Assignment
Treatment
Uncontrolled
